Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease.
Previous studies suggest the presence of increased concentrations of cerebral myo-inositol in Alzheimer disease (AD). To characterize this abnormality further, we quantified myo-inositol and several other polyols in cerebrospinal fluid (CSF) and plasma from 10 AD subjects and 10 healthy age-matched controls by using a gas chromatographic-mass spectrometric technique. The mean CSF concentration and CSF/plasma concentration ratio of myo-inositol in AD were not significantly different from those determined in control subjects. Also, concentration profiles of other polyols were not significantly altered in AD. CSF and plasma myo-inositol concentrations were correlated in control subjects but not in AD subjects. However, a significant correlation between CSF and plasma 1,5-anhydrosorbitol (a polyol internal control) concentrations observed in control subjects was retained in AD subjects.
Shetty
H U
HU
Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892-1582, USA.
Holloway
H W
HW
Schapiro
M B
MB
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood* / Q000134:cerebrospinal fluid*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007294:Inositol / Q000097:blood* / Q000134:cerebrospinal fluid*; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D012016:Reference Values; D013402:Sugar Alcohols / Q000097:blood* / Q000134:cerebrospinal fluid*
D013402:Sugar Alcohols; D007294:Inositol